Internationalization is an important way to build the international influence of
Chinese medicine.
It is reported that at the 5th China International Import Expo recently, Boji Pharma and AstraZeneca Pharmaceutical (Chengdu) Co.
, Ltd.
"held hands", the two sides will work together to build a highland of traditional Chinese medicine industry, in Chengdu high-tech zone to lay out a new type of R & D transformation institution, and Boji Pharmaceutical will provide AstraZeneca with traditional Chinese medicine research and development (including pharmaceutical research, non-clinical research, clinical research, registration services and other whole process) and other services, promote the research and development of new Chinese medicines, secondary development of traditional Chinese medicines and other matters
.
According to the data, Boji Pharmaceutical is a listed company
that provides domestic and foreign pharmaceutical enterprises with "one-stop" outsourcing services (CRO+CDMO) for the whole process of drug and medical device R&D and production.
Traditional Chinese medicine is one of the treasures of Chinese civilization, embodying the broad wisdom
of the Chinese people and the Chinese nation.
In recent years, the state has issued a series of encouragement and support policies for traditional Chinese medicine, and the "14th Five-Year Plan" emphasizes key areas to tackle key problems, strengthen the cooperation between the Chinese medicine research institute and enterprises, scientific research institutions, etc.
, accelerate the progress of new drug research and development, optimize the registration and management of traditional Chinese medicine preparations, etc.
, which is beneficial to traditional Chinese medicine enterprises and also brings a broad market space
for the CRO business of traditional Chinese medicine with local Chinese characteristics.
Compared with the research and development of new drugs of chemical drugs, the research and development of traditional Chinese medicines is more complicated, Boji Pharmaceutical, as an early start-up enterprise in the field of traditional Chinese medicine CRO, traditional Chinese medicine CRO has now accounted for about 20% of the company's overall revenue, and the company maintains more than 20 important clinical projects with a certain scale every year, including many promising projects
such as ginkgolide B injection and saltpeter granules of class 1.
2 new drugs of traditional Chinese medicine.
In the field of innovative Chinese medicine drugs, Boji Pharma helped customers obtain 5 clinical approvals for innovative Chinese medicine drugs
in 2021.
In order to improve the R&D capability and service level of traditional Chinese medicine, in 2021, Boji Pharmaceutical integrated the clinical and preclinical business of traditional Chinese medicine into its wholly-owned subsidiary Xinglin Traditional Chinese Medicine, and cooperated with Nanchang, Nanyang and other local governments to jointly build a traditional Chinese medicine innovative drug industrial park, build an integrated service platform for traditional Chinese medicine innovative drugs (CRO+CDMO+ incubator), and help the development of
innovative Chinese medicine industry.
In terms of talent team building, Boji Pharma also attaches great importance to the company's large-scale, professional and mature clinical research team, which can provide clinical trial full-process solutions
including medicine, project management, monitoring, audit, data management and statistical analysis, and biological sample testing.
Data show that the proportion of doctoral and master's degrees among the company's employees is nearly 16%.
Among them, most of the core technical personnel and consultant team of clinical business have master's degree or above; The proportion of doctoral masters in preclinical business is about 30%, and the proportion of doctoral masters in preclinical business of innovative drugs is about
50%.
Behind the "hand-in-hand" between AstraZeneca and the company, it can be seen that it recognizes the company's strength and further lays out
the traditional Chinese medicine industry.
On April 22 this year, Chengdu High-tech Zone and AstraZeneca held an online signing ceremony for AstraZeneca Traditional Chinese Medicine Innovation Industry Base, which will focus on the modern industry of traditional Chinese medicine, which is another important attempt
in the traditional Chinese medicine industry after AstraZeneca reached a promotion cooperation with Luye Group in 2019.
The industry believes that with the aging of China's population and the increase in the incidence of chronic diseases, the market demand for traditional Chinese medicine is huge
.
At the same time, the road of modernization of traditional Chinese medicine also needs to "go global" and open up overseas markets
.
Relying on their industry status, international platforms and industrial resources, multinational pharmaceutical companies can help the international development of
traditional Chinese medicine.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
